Rodman & Renshaw maintained its Market Perform rating on Catalyst Pharmaceutical Partners CPRX. In a research report published today, Rodman & Renshaw stressed it remains cautiously optimistic about the performance of some of Catalyst's new drugs.
In the report, Rodman & Renshaw states, "We are cautiously optimistic about the new Phase 2b study of CPP-109, and believe that if approved, CPP-109 may have a
substantial commercial value in the addiction market. Additionally, the preclinical data suggests that CPP-115 (wider
therapeutic window, longer patent life, new indications) may be an excellent follow-on drug to CPP-109. We look forward to
future updates on the development of the company's pipeline."
On Thursday, Catalyst added 1.14% to its value to close the day at $1.78. Its shares lost all of yesterday's gains in today's pre-market trading, however, sliding 4.49% to $1.70.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsCatalyst Pharmaceutical PartnersHealth CarePharmaceuticalsRodman & Renshaw
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in